The effect of metformin on breast density
- Conditions
- Breast density.
- Registration Number
- IRCT20100706004329N9
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 146
Female gender
Age over 40 years
Suspicion of malignancy
Used of drugs that affect metabolic status, such as weight, glucose, and lipid-lowering agents During the study or three months before the study
History of breast cancer
Proven or suspected pregnancy and lactation during the intervention
Other medical conditions, such as cardiovascular disease, epilepsy, renal or hepatic disorders
Contraindications for metformin use (such as hypersensitivity to biguanides, acidemia, heart disease, alcohol consumption, gastroparesis, hepatic disease, hyperthyroidism or hypothyroidism, severe iron deficiency anemia, renal impairments)
History of unwanted and intolerable side effects of metformin (such as abdominal pain, chest pain, chills, cholestasis, diarrhea, dizziness, increased liver enzymes, severe headache, hepatitis, hypoglycemia, megaloblastic anemia, myalgia, nausea, Palpitations, rash, rash, vomiting)
Suffering from hormonal disorders and metabolic diseases such as hypo or hyperthyroidism, metabolic syndrome, diabetes, severe hyperlipidemia, galactorrhea
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Breast density. Timepoint: At the beginning of the study (before the intervention) and six months after the intervention. Method of measurement: Mammography scan.
- Secondary Outcome Measures
Name Time Method